SCHEMBL4707352

SCHEMBL4707352

CCn1nc(-c2ccccc2)c(C(C)=O)c(Nc2ccc(F)c(Cl)c2)c1=O

nearest known ligand 0.69

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 1/20 0.69
MAPT P10636 2/20 0.50
IDO1 P14902 3/20 0.44
HTR1A P08908 3/20 0.43
ADRA1D P25100 3/20 0.43
ADRA1A P35348 3/20 0.43
ADRA1B P35368 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
LMNA P02545 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3038058 0.91 PDE4B (0.57) PDE4BMAPTIDO1SMN1; SMN2NPC1
SCHEMBL4708657 0.91 PDE4B (0.73) PDE4BMAPTHTR1AADRA1DADRA1A
SCHEMBL4708694 0.91 PDE4B (0.73) PDE4BMAPTHTR1AADRA1DADRA1A
SCHEMBL3029107 0.90 PDE4B (0.56) PDE4BMAPTNPC1RAB9ALMNA
SCHEMBL4705519 0.89 PDE4B (0.70) PDE4BMAPTHTR1AADRA1DADRA1A
SCHEMBL4708425 0.89 PDE4B (0.72) PDE4BMAPTHTR1AADRA1DADRA1A
SCHEMBL4708776 0.88 PDE4B (0.80) PDE4BHTR1AADRA1DADRA1AADRA1B
SCHEMBL4707375 0.87 PDE4B (0.70) PDE4BMAPTHTR1AADRA1DADRA1A
SCHEMBL4708875 0.87 PDE4B (0.70) PDE4BMAPTHTR1AADRA1DADRA1A
SCHEMBL4058811 0.87 PDE4B (0.70) PDE4BMAPTHTR1AADRA1DADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7459453-B2 Pyridazin-3(2H)-one derivatives as PDE4 inhibitors LABORATORIOS ALMIRALL, S.A. (ES) 2008-12-02 US disclosed
US-20080269235-A1 PYRIDAZIN-3 (2H) -ONE DERIVATIVES AS PDE4 INHIBITORS DAL PIAZ VITTORIO 2008-10-30 US disclosed
US-20060052379-A1 Pyridazin-3(2h)-one derivatives as pde4 inhibitors LABORATORIOS ALMIRALL, S.A. (ES) 2006-03-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269235-A1 PYRIDAZIN-3 (2H) -ONE DERIVATIVES AS PDE4 INHIBITORS PDE4A, PDE3A, PDE4B PDE4B 3/4885MAPT 3692/4885IDO1 985/4885
US-20060052379-A1 Pyridazin-3(2h)-one derivatives as pde4 inhibitors PDE4A, PDE3A, PDE4B PDE4B 3/4885MAPT 3692/4885IDO1 985/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.